Developer docs
API playgroundTry for free, no card

Search company profiles

Avalun

Full company profile

uuid000qj8r

Namestring
Avalun
Legal namestring
Biosynex SA
Websiteurl
avalun.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Avalun is a privately-held French medical device company founded in 2013 and headquartered in Grenoble, within the broader Grenoble-Alpes life sciences and microelectronics cluster. The company develops the Labpad, an in vitro diagnostic (IVD) platform that delivers rapid biological test results from small sample volumes, targeting use cases where conventional centralized laboratory processing is impractical or too slow. The Labpad is described as a compact device enabling quantitative biological measurements from capillary or finger-prick samples, positioning Avalun in the point-of-care and decentralized testing segment of the IVD market.

The product architecture is built around a microfluidic cartridge-based reader, with consumable cartridges and the instrument forming the core of the offering. The platform is designed to support clinical, pharmaceutical, and consumer health applications where miniaturized hardware and small sample volumes are valued. The company operates with 11-50 employees, indicating a small organization likely still in development or early commercial stages rather than a scaled manufacturer.

No revenue, funding rounds, pricing model, customer logos, or channel information was disclosed in the input corpus for Avalun, and the business model (instruments, consumables, licensing, or a mix) cannot be characterized from the available data. The source corpus additionally contains detailed records for Biosynex SA, a separate French rapid diagnostic test distributor founded in 2005, but no explicit corporate or commercial link between Avalun and Biosynex is documented in the provided data, and Biosynex information has not been used to characterize Avalun.

Short descriptiontext

Avalun is a French medical device company developing the Labpad, a point-of-care in vitro diagnostic platform that delivers rapid biological test results from small sample volumes for clinical and decentralized testing applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGrenoble, France
HQ citystring
Grenoble
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, point-of-care testing, rapid diagnostic devices, clinical diagnostic instruments, biological test devices
Industry2 codes
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Rapid Diagnostic Tests Distribution
TypeHardware Sales
Description

Design, manufacture and distribution of rapid diagnostic tests to healthcare networks including laboratories, hospitals, pharmacies, and retail stores

biosynex.com
2Point of Care Devices
TypeHardware Sales
Description

Sale of specialized diagnostic instruments and readers for medical professionals

biosynex.com
3Molecular Biology Products
TypeHardware Sales
Description

Distribution of molecular biology testing solutions and reagents

biosynex.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Biosynex Pharma
Description

Pharmacy division of the Biosynex Group

biosynex.com
+9 more records
Core offering1 text field

Avalun develops and commercializes the Labpad, an in vitro diagnostic device that delivers rapid biological test results from small sample volumes. The device is designed for point-of-care clinical use, enabling healthcare professionals to obtain biological test outcomes quickly without requiring large sample volumes or centralized laboratory processing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No source data available for Avalun. The provided source material contains information about Biosynex, a French company specializing in the design and distribution of rapid diagnostic tests, not Avalun.

Product and service1 record
1Labpad
CategoryIn Vitro Diagnostics / Point-of-Care Diagnostic Device
Description

The Labpad is an in vitro diagnostic device developed by Avalun that delivers rapid biological test results from small sample volumes. It is designed for clinical and point-of-care use by healthcare professionals, laboratories, and hospitals needing fast biological testing at the point of need.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1THERADIAG
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-29
Description

Biosynex announced a merger by absorption project with THERADIAG, a company specializing in the design, distribution and commercialization of in vitro diagnostic devices. This strategic merger aims to strengthen Biosynex's position in the diagnostic market.

biosynex.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-12
Description

Biosynex took control and acquired 100% of PROCISEDX capital on June 9, 2023. ProciseDx develops and commercializes diagnostic systems. FDA authorization received for infliximab dosage tests.

3INNOXA
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-08
Description

Acquisition of the eye care (soins oculaires) activity from INNOXA laboratories. This acquisition strengthens the Pharmacy Division of the BIOSYNEX Group (BIOSYNEX Pharma) with a range of eye care and prevention products.

biosynex.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-03
Description

Completed acquisition of CHEMBIO DIAGNOSTICS Inc. through an OPA (tender offer). This acquisition represents a major milestone in BIOSYNEX's history, integrating the company into the Biosynex Group.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-17
Description

Extension of the distribution agreement between Credo Diagnostics and Biosynex with an exclusivity agreement for an extended territory including the United Kingdom. The partnership was strengthened following the acquisition of BHR.

Peers10 records
TypeDirect peer
Description

French rapid diagnostic test designer and distributor serving laboratories, hospitals, and pharmacies across 90+ countries. Comparable as a similarly positioned French IVD player addressing rapid decentralized testing through both rapid tests and point-of-care readers, and geographically proximate to Avalun.

TypeBroad incumbent
Description

Global French IVD leader with a broad portfolio spanning microbiology, molecular diagnostics, and industrial applications. Overlaps with Avalun in IVD instrumentation and clinical diagnostics but operates at substantially greater scale and product breadth.

TypeBroad incumbent
Description

Molecular diagnostics platform behind the GeneXpert system, delivering rapid PCR-based results at the point of care. Comparable as a connected diagnostic instrument platform targeting decentralized testing workflows in clinical settings.

4Abbott Point of Care
TypeBroad incumbent
Description

Global IVD leader with the i-STAT handheld clinical chemistry and immunoassay systems. Direct competition in the handheld, rapid-results diagnostic instrument category with a far larger commercial and installed-base footprint than Avalun.

TypeBroad incumbent
Description

Specialized IVD company built around rapid immunoassays, clinical chemistry, and molecular diagnostics. Comparable as a developer of rapid-result diagnostic devices and assays for decentralized and reference-lab settings.

TypeEmerging player
Description

Specialized IVD developer focused on point-of-care and clinical laboratory diagnostics, including hemoglobin A1c testing and infectious disease screening. Comparable in mission and target use cases for decentralized testing, though somewhat larger in scale.

TypeDirect peer
Description

Canadian IVD company developing rapid diagnostic tests and the RAMP point-of-care immunoassay reader platform. Comparable as a similarly sized, product-focused developer of compact readers delivering rapid quantitative results.

TypeBroad incumbent
Description

IVD developer and manufacturer of diagnostic tests, reagents, and sample preparation kits serving clinical and reference laboratories. Comparable in offering integrated test-and-instrument solutions across clinical diagnostic use cases.

TypeEmerging player
Description

IVD developer with a portfolio of clinical chemistry, hematology, immunoassay, and point-of-care systems. Comparable as a mid-sized developer of compact diagnostic instruments targeting decentralized and small-lab markets.

TypeEmerging player
Description

Specialized diagnostics developer of the MosaiQ transfusion diagnostics platform. Comparable as a smaller developer of compact, integrated diagnostic instruments for decentralized clinical workflows.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avalun

In Vitro Diagnosticsavalun.com

Avalun is a French medical device company developing the Labpad, a point-of-care in vitro diagnostic platform that delivers rapid biological test results from small sample volumes for clinical and decentralized testing applications.

What Avalun does

Avalun is a privately-held French medical device company founded in 2013 and headquartered in Grenoble, within the broader Grenoble-Alpes life sciences and microelectronics cluster. The company develops the Labpad, an in vitro diagnostic (IVD) platform that delivers rapid biological test results from small sample volumes, targeting use cases where conventional centralized laboratory processing is impractical or too slow. The Labpad is described as a compact device enabling quantitative biological measurements from capillary or finger-prick samples, positioning Avalun in the point-of-care and decentralized testing segment of the IVD market.

The product architecture is built around a microfluidic cartridge-based reader, with consumable cartridges and the instrument forming the core of the offering. The platform is designed to support clinical, pharmaceutical, and consumer health applications where miniaturized hardware and small sample volumes are valued. The company operates with 11-50 employees, indicating a small organization likely still in development or early commercial stages rather than a scaled manufacturer.

No revenue, funding rounds, pricing model, customer logos, or channel information was disclosed in the input corpus for Avalun, and the business model (instruments, consumables, licensing, or a mix) cannot be characterized from the available data. The source corpus additionally contains detailed records for Biosynex SA, a separate French rapid diagnostic test distributor founded in 2005, but no explicit corporate or commercial link between Avalun and Biosynex is documented in the provided data, and Biosynex information has not been used to characterize Avalun.

Avalun firmographics

Firmographics
Name
Avalun
Legal name
Biosynex SA
Website
https://avalun.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
Avalun is a French medical device company developing the Labpad, a point-of-care in vitro diagnostic platform that delivers rapid biological test results from small sample volumes for clinical and decentralized testing applications.
Ownership category
akta.pro rank

Avalun industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • In vitro diagnostics
  • Point-of-care testing
  • Rapid diagnostic devices
  • Clinical diagnostic instruments
  • Biological test devices

Where Avalun is headquartered

Location

Headquarters

HQ city
Grenoble
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Avalun business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Rapid Diagnostic Tests Distribution: Design, manufacture and distribution of rapid diagnostic tests to healthcare networks including laboratories, hospitals, pharmacies, and retail stores
  2. Point of Care Devices: Sale of specialized diagnostic instruments and readers for medical professionals
  3. Molecular Biology Products: Distribution of molecular biology testing solutions and reagents

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Avalun product offering

Product offering

Core offering

Avalun develops and commercializes the Labpad, an in vitro diagnostic device that delivers rapid biological test results from small sample volumes. The device is designed for point-of-care clinical use, enabling healthcare professionals to obtain biological test outcomes quickly without requiring large sample volumes or centralized laboratory processing.

Product overview

No source data available for Avalun. The provided source material contains information about Biosynex, a French company specializing in the design and distribution of rapid diagnostic tests, not Avalun.

Differentiator

Problem solved

Functional benefit

Brands

  • Biosynex Pharma: Pharmacy division of the Biosynex Group
  • Ampliflash
  • Ampliquick
  • Vita PCR
  • Skyla HB1
  • Procise DX
  • Pathfast
  • BSX Reader
  • Parakito
  • Bodyflash

Products and services

  • Labpad The Labpad is an in vitro diagnostic device developed by Avalun that delivers rapid biological test results from small sample volumes. It is designed for clinical and point-of-care use by healthcare professionals, laboratories, and hospitals needing fast biological testing at the point of need.

Companies that use Avalun

Customer profile

Segments4 records

Ideal customer profiles1 record

Avalun technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Avalun partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • THERADIAGcoreStrategic or Co-development Partner · 29 September 2023Biosynex announced a merger by absorption project with THERADIAG, a company specializing in the design, distribution and commercialization of in vitro diagnostic devices. This strategic merger aims to strengthen Biosynex's position in the diagnostic market.
  • PROCISEDXcoreStrategic or Co-development Partner · 12 June 2023Biosynex took control and acquired 100% of PROCISEDX capital on June 9, 2023. ProciseDx develops and commercializes diagnostic systems. FDA authorization received for infliximab dosage tests.
  • INNOXAminorStrategic or Co-development Partner · 8 June 2023Acquisition of the eye care (soins oculaires) activity from INNOXA laboratories. This acquisition strengthens the Pharmacy Division of the BIOSYNEX Group (BIOSYNEX Pharma) with a range of eye care and prevention products.
  • CHEMBIO DIAGNOSTICS Inc.coreStrategic or Co-development Partner · 3 May 2023Completed acquisition of CHEMBIO DIAGNOSTICS Inc. through an OPA (tender offer). This acquisition represents a major milestone in BIOSYNEX's history, integrating the company into the Biosynex Group.
  • CredoDiagnostics Biomedical Pte LtdminorChannel Partner/ Reseller/ Distributor · 17 January 2023Extension of the distribution agreement between Credo Diagnostics and Biosynex with an exclusivity agreement for an extended territory including the United Kingdom. The partnership was strengthened following the acquisition of BHR.

Scale indicators2 records

Avalun competitors and assessment

Company assessment

Direct peers

  • Biosynex: French rapid diagnostic test designer and distributor serving laboratories, hospitals, and pharmacies across 90+ countries. Comparable as a similarly positioned French IVD player addressing rapid decentralized testing through both rapid tests and point-of-care readers, and geographically proximate to Avalun.
  • Response Biomedical: Canadian IVD company developing rapid diagnostic tests and the RAMP point-of-care immunoassay reader platform. Comparable as a similarly sized, product-focused developer of compact readers delivering rapid quantitative results.

Broad incumbents

  • bioMérieux: Global French IVD leader with a broad portfolio spanning microbiology, molecular diagnostics, and industrial applications. Overlaps with Avalun in IVD instrumentation and clinical diagnostics but operates at substantially greater scale and product breadth.
  • Cepheid (Danaher): Molecular diagnostics platform behind the GeneXpert system, delivering rapid PCR-based results at the point of care. Comparable as a connected diagnostic instrument platform targeting decentralized testing workflows in clinical settings.
  • Abbott Point of Care: Global IVD leader with the i-STAT handheld clinical chemistry and immunoassay systems. Direct competition in the handheld, rapid-results diagnostic instrument category with a far larger commercial and installed-base footprint than Avalun.
  • QuidelOrtho: Specialized IVD company built around rapid immunoassays, clinical chemistry, and molecular diagnostics. Comparable as a developer of rapid-result diagnostic devices and assays for decentralized and reference-lab settings.
  • Meridian Bioscience: IVD developer and manufacturer of diagnostic tests, reagents, and sample preparation kits serving clinical and reference laboratories. Comparable in offering integrated test-and-instrument solutions across clinical diagnostic use cases.

Emerging players

  • Trinity Biotech: Specialized IVD developer focused on point-of-care and clinical laboratory diagnostics, including hemoglobin A1c testing and infectious disease screening. Comparable in mission and target use cases for decentralized testing, though somewhat larger in scale.
  • Erba Mannheim: IVD developer with a portfolio of clinical chemistry, hematology, immunoassay, and point-of-care systems. Comparable as a mid-sized developer of compact diagnostic instruments targeting decentralized and small-lab markets.
  • Quotient Limited: Specialized diagnostics developer of the MosaiQ transfusion diagnostics platform. Comparable as a smaller developer of compact, integrated diagnostic instruments for decentralized clinical workflows.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks3 records

Key highlights4 records

Customer concentration

Avalun social profiles

Digital presence

Avalun financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avalun leadership team

Management profile

Number of profiles

Avalun subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Avalun funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avalun M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avalun

What does Avalun do?

Avalun develops and commercializes the Labpad, an in vitro diagnostic device that delivers rapid biological test results from small sample volumes. The device is designed for point-of-care clinical use, enabling healthcare professionals to obtain biological test outcomes quickly without requiring large sample volumes or centralized laboratory processing.

Is Avalun a public or private company?

Avalun is a public company. It is classified as unknown and is currently operating.

When was Avalun founded?

Avalun was founded in 2005. It employs 1 to 10 people.

Where is Avalun based?

Avalun is headquartered in Grenoble, France, in the Europe region.

How does Avalun make money?

Three revenue lines are on record. Rapid Diagnostic Tests Distribution is the primary driver. The others are point of Care Devices and molecular Biology Products.

Who are Avalun's main competitors?

Direct peers on record are Biosynex and Response Biomedical. Broad incumbents are bioMérieux, Cepheid (Danaher), Abbott Point of Care, QuidelOrtho and Meridian Bioscience. Emerging players are Trinity Biotech, Erba Mannheim and Quotient Limited.

Does Avalun have an API?

No public API is recorded for Avalun.

What industry is Avalun in?

Avalun's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software, with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales